Evidence map›Paper›PMID 32854624›Full record

ArticleBMC cardiovascular disorders2020

Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series.

Małgorzata Dybowska, Monika Szturmowicz, Lucyna Opoka, Piotr Rudziński, Witold Tomkowski

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC cardiovascular disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Fibrinolytic Therapy in Purulent Pericarditis.Reviews in cardiovascular medicine · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Małgorzata DybowskaI Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, ul Plocka 26, 01-138, Warsaw, Poland. dybowska@mp.pl.ORCID 0000-0003-0893-3625
Monika SzturmowiczI Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, ul Plocka 26, 01-138, Warsaw, Poland.
Lucyna OpokaDepartment of Radiology, National Tuberculosis and Lung Diseases Research Institute, Plocka 26, 01-138, Warsaw, Poland.
Piotr RudzińskiDepartment of Thoracic Surgery, National Tuberculosis and Lung Diseases Research Institute, Plocka 26, 01-138, Warsaw, Poland.
Witold TomkowskiI Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, ul Plocka 26, 01-138, Warsaw, Poland.
National Center for Tuberculosis and Lung Disease · GE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis. CASE PRESENTATION: We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA) was used. Management of PP requires a combined surgical and medical approach. The most important is complete drainage of the effusion by subxiphoid pericardiotomy connected with complementary use of broad-spectrum antibiotics. Despite the use of broad- spectrum antibiotics, in some patients a large volume of daily drainage is still present. Constrictive pericarditis as a complication of PP is observed in majority of patients. Intrapericardial administration of fibrinolytic agents, although not strongly recommended, can improve efficacy of antibiotic treatment especially in patients with loculation fluid and can prevent the development of constrictive pericarditis. r-tPA was applied at a dose of 20 mg dissolved in 100 ml of normal saline in a 100 ml syringe, administered by a large pericardial drain (Pezzer drain) installed into the pericardial cavity during pericardioscopy. The tube was closed and re-opened after 24 h. No serious complications, such as bleeding, allergy or hypotension, were noted.

conclusionWe present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA), prevented the development of constrictive pericarditis, and increased efficacy of antibiotic treatment without any significant complications.

Indexed as

AdultAgedAnti-Bacterial AgentsFemaleFibrinolytic AgentsHumansMaleMiddle AgedPericardiectomyPericarditisPericarditis, ConstrictiveRecombinant ProteinsTissue Plasminogen ActivatorTreatment OutcomeAnti-Bacterial AgentsFibrinolytic AgentsRecombinant ProteinsTissue Plasminogen ActivatorConstrictive pericarditisFibrinolysisPurulent pericarditisSubxiphoid pericardiotomy

Identifiers

PMID32854624
PMCPMC7451238
OpenAlexW3081782334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.